MedTrace Logo

The Use of a Water Soluble Under the Tongue (Sublingual) CBD Tablet for Treating Pain Associated With Diabetic Peripheral Neuropathy

NCT04088929 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2019-12-11

No results posted yet for this study

Summary

Use of Cannabidiol for the treatment of Diabetic Neuropathic Pain.

Conditions

  • Diabetic Neuropathies

Interventions

DRUG

CBD

A water-soluble sublingual tablet containing 20 mg of cannabidiol (CBD) and 0.1 mg of a proprietary blend of terpenes.

Sponsors & Collaborators

  • Pure Green

    lead INDUSTRY

Principal Investigators

  • Debra Kimless, M.D. · Pure Green, LLC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-30
Primary Completion
2019-11-22
Completion
2019-12-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04088929 on ClinicalTrials.gov